— Know what they know.
Not Investment Advice
Also trades as: 0A55.L (LSE) · $vol 0M

QDEL NASDAQ

QuidelOrtho Corporation
1W: +7.9% 1M: +25.9% 3M: -17.4% YTD: -52.1% 1Y: -53.8% 3Y: -79.5% 5Y: -89.2%
$13.59
-0.18 (-1.31%)
After Hours: $13.77 (+0.18, +1.29%)
Weekly Expected Move ±11.3%
$11 $12 $14 $15 $17
NASDAQ · Healthcare · Medical - Specialties · Tech Score Buy · Power 61 · $944.3M mcap · 68M float · 2.47% daily turnover · Short 41% of daily vol
Credit Risk of going bust: higher than 94% of companies Debt: 76.5% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the riskiest tenth, about 1 in 20 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $4.14 (down 70%), QuidelOrtho Corporation would be worth roughly what it owes.
Total debt $3.08B against a stock market value of $944.3M.
Distance to default 0.97 (Merton model): prices to 2026-10-26, balance sheet 2026-06-28, debt counted $1.66B (short-term plus half of long-term), stock volatility 92.6%; Altman Z'' -0.74. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Smart Money Score
Moderate 50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$944.3M
52W Range9.92-35.58
Volume2,178,724
Avg Volume1,679,977
Beta0.68
Dividend—
Analyst Ratings
6 Buy 7 Hold 2 Sell
Consensus Hold
Company Info
CEOBrian J. Blaser
Employees6,500
SectorHealthcare
IndustryMedical - Specialties
IPO Date1991-02-01
9975 Summers Ridge Road
San Diego, CA 92121
US
858 552 1100
About QuidelOrtho Corporation

QuidelOrtho Corporation specializes in the creation and production of diagnostic testing solutions, addressing a wide array of healthcare testing demands. The company operates through distinct business units. Its Labs division provides clinical chemistry and immunoassay instruments and tests designed to analyze bodily fluids and proteins, aiding in health assessment, patient management, and tracking disease progression. The Transfusion Medicine unit focuses on ensuring blood safety and compatibility by offering immunohematology and infectious disease screening tests for blood and plasma. For rapid results in various clinical environments, the Point-of-Care segment delivers quick diagnostic tests. Additionally, the Molecular Diagnostics arm develops advanced polymerase chain reaction thermocyclers, analyzers, and amplification systems. QuidelOrtho distributes its offerings both directly to end-users and through an extensive network of distributors. These products are utilized by professionals in settings such as medical offices, hospitals, clinical and reference laboratories, urgent care centers, universities, retail clinics, pharmacies, wellness screening centers, and blood/donor banks, as well as for individual, non-professional, and over-the-counter applications. Founded in 1979 and based in San Diego, California, the company maintains a global footprint, including operations across North America, Europe, the Middle East, Africa, and China.

Recent Insider Trades

NameTypeSharesPriceDate
Siegrist Jonathan Ph M-Exempt 18,657 — 2026-10-15
Siegrist Jonathan Ph F-InKind 6,695 $13.91 2026-10-15
Siegrist Jonathan Ph M-Exempt 18,657 — 2026-10-15
Bowman Ronald Lee M-Exempt 2,566 — 2026-09-15
Bowman Ronald Lee F-InKind 921 $10.63 2026-09-15

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms